ArticleiScience2025
Integrative multi-omics analysis decodes HOXC9-driven malignant transformation and metastasis in OSCC.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HOXC9 promotes cell proliferation and suppresses mitochondria-dependent apoptosis through the AKT/mTOR pathway in esophageal squamous cell carcinoma.Molecular and cellular biochemistry · 2026Article
- HOXC9 transcriptionally activates NRP1 to promote cell malignant progression and immune evasion in colorectal cancer.Molecular genetics and genomics : MGG · 2026Article
- Dissecting the role of epigenetic regulation in oral squamous cell carcinoma microenvironment: mechanisms and therapeutics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is a highly prevalent head and neck malignancy with a poor prognosis, often exhibiting resistance to conventional therapies. This highlights an urgent need for reliable biomarkers to facilitate early detection and effective management of recurrent or metastatic cases. Leveraging multi-omics analysis, we identified the HOX gene family as significantly overexpressed and closely associated with OSCC progression. Among these, HOXC9 was prioritized as a key regulator using machine learning algorithms. Mechanistic investigations revealed a strong correlation between HOXC9 expression and DNA hypomethylation at the CDX1 motif, which play a crucial role in regulating MMP13 expression. Single-cell RNA sequencing further elucidated the role of HOXC9 in driving OSCC malignant transformation. Clinical evidence demonstrates that HOXC9 promotes OSCC invasion and metastasis through the ITGA6/PI3K/Akt/MMP13 signaling axis. Additionally, HOXC9 expression appears to be modulated by miR-196, presenting a potential target for therapeutic intervention in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.